Login to Your Account

Compliance, Burn Problems Solved?

Dry-Eye Phase III Trial Enrolled, OphthaliX 'Wets' Oral Appetite

By Randy Osborne
Staff Writer

Tuesday, March 19, 2013

Dry-eye syndrome (DES) was not the first indication that OphthaliX Inc. planned to tackle with its first-in-class A3 adenosine receptor agonist CF101, though a 24-week, 236-patient, placebo-controlled Phase III trial is already enrolled, from which data are expected to spill out by the fourth quarter of this year.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription